Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $14.67

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $14.67.

ZURA has been the topic of several research reports. Oppenheimer restated an “outperform” rating and set a $19.00 price objective (down previously from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Guggenheim restated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research report on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating on shares of Zura Bio in a research report on Thursday, April 3rd. Chardan Capital lowered their price objective on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th.

Zura Bio Stock Performance

Shares of NASDAQ ZURA opened at $1.13 on Friday. The stock has a fifty day moving average of $1.37 and a 200-day moving average of $2.57. The stock has a market cap of $77.26 million, a PE ratio of -2.13 and a beta of 0.08. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.09. The firm had revenue of $0.00 million during the quarter. On average, sell-side analysts predict that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Several institutional investors have recently added to or reduced their stakes in the company. American Century Companies Inc. bought a new stake in shares of Zura Bio in the fourth quarter worth about $27,000. Prudential Financial Inc. bought a new stake in shares of Zura Bio in the 4th quarter worth approximately $28,000. Two Sigma Advisers LP purchased a new position in shares of Zura Bio during the fourth quarter valued at approximately $32,000. ProShare Advisors LLC bought a new position in shares of Zura Bio during the fourth quarter valued at approximately $35,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Zura Bio in the third quarter worth $71,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.